Recent investigations have centered on the intersection of GLP-1|GIP|glucagon receptor stimulant therapies and dopaminergic neurotransmission. While GLP activators are widely employed for treating type 2 T2DM, their unexpected effects on motivation circuits, specifically mediated by dopamine pathways, are attracting considerable attention. This pap